View Larger Image
Updated: Dec 9 2011
Molecular Targeting Technologies, Inc. (MTTI) is a privately-held biotechnology company focused on the development of diagnostic and therapeutic molecules for cancer and infection.
Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?
Be sure to add update@genengnewsemail.com to your Address Book or Safe Senders List.
Click here for instructions.
If you have any questions about your subscription, click here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable resource for everyone involved in the business of translating discoveries at the bench into solutions that fight disease and improve health, agriculture, and the environment. Subscribe today to see why over 60,000 biotech professionals read GEN to keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery, bioprocessing, molecular diagnostics, collaborations, biotech business trends, and more.
© 2013 Genetic Engineering & Biotechnology News All Rights Reserved